Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cortex (Cor) [formerly CORX] -- Ignore unavailable to you. Want to Upgrade?

To: Cavalry who wrote (629)	10/24/1998 5:08:00 PM
From: Cage Rattler	Respond to of 1255

Cav: Of course. Last week's news release, the CFO's departure -- bad times. Still a drive by and direct contact may still be just the ticket. There is a chance that management is just stupid rather than devious. With this great news published CORX, could drop to .25. If conversely the product is genuine, we may have to change our thinking and consider a hostile take-over rather than a buy out -- SOB. Look for little or no drop in price Monday indicating strange smells on the wind from Denmark. CEOs should always be up front with small caps, at least in my opinion. Remember from a technical point of view, the price-volume equation has been strange at best. If a take-over turns out to be the case, it will tragic that management alienated the stock holders by keeping everyone in the dark. This stock gets more interesting by the day/hour. Please keep me up to date. Ciao, Ted

To: Cavalry who wrote (629)	10/24/1998 6:42:00 PM
From: DavidCG	Read Replies (1) \| Respond to of 1255

Cortex takes a proactive stance and submits a plan to Nasdaq to stay on Nasdaq. Not a reactive one. In addition, Cortex is talking to four multi-national corporations. And if they are talking to four of them... Cortex is playing them against each other. Cav, if you like heb, sell corx and buy your heb! I think that's a pretty simple concept. You're comparing your stock worth $160 million to a stock worth $6 million. There simply is no comparison. Find another neurological company worth $6-$20 million market cap..then you can have a logical discussion by comparing the two. How about I compare HEB to PFE (Pfizer)with a market cap of $141 BILLION.. PFE is simply better....compare apples to apples please. And if you are worried corx is going to be worth less pretty soon... is there any reason to hold it? Nope. So sell. The worst thing that can happen is hold on to a stock with "hope". Your LA article says exactly what CORX's news release did. And if you think about it, you are placing too much emphasis on the Nasdaq listing. CORX is now .65 a share... doesn't really matter if it gets delisted...should that ever occur. Delisting doesn't affect the price.. you should know that. Especially if you ran with CYGS up to $3. As for DGIV and CYGS. Bought both at about .40 and sold at $4 and $2.50 respectively. No complaints here. -DavidCG